REPROTOX

Teratology service

Reproductive Toxicology Center, a US nonprofit · United States

Visit the source site · Audited 2026-10-14

Who pays for it

REPROTOX earns subscription income; its fiscal year ending June 2026 reported $776,465 in revenue and $207,714 in contributions, whose sources are not named in the public summary.

Status: Supporting

Its expert-written summaries cite studies and show update dates, but public pages do not name all contributors or disclose entry-level conflicts. SafeMomma lists REPROTOX as supporting if access is licensed, so key claims need an independent source and the cited research.

How SafeMomma uses it

We use its summaries as a supporting view and check cited studies and a source with different owners and funding, since some findings may share OTIS study results.

The audit

Who controls it: REPROTOX is a service of the Reproductive Toxicology Center, a US nonprofit. Its About page says staff write, update, and review summaries, and lists expertise in toxicology, genetics, pharmacology, reproductive psychiatry, and reproductive development; the reviewed pages do not describe an external editorial board.
Money: REPROTOX receives subscription income from consumers, practitioners, and institutions, including for-profit institutions. Its fiscal year ending June 2026 reported $776,465 in revenue and $207,714 in contributions, but the public summary does not name contributors. Public prices range from $17 per month for consumers to $20,000 per year for 500-plus users at for-profit institutions.
Conflict rules: The audit found no public REPROTOX-wide conflict policy or entry-level author disclosure. This is a gap in public disclosure, not proof that no internal policy exists.
Method: REPROTOX says it summarizes human, animal, and laboratory research on fertility, pregnancy, lactation, and development. A sample entry gives numbered references, but the reviewed pages do not describe a formal evidence scale or full method for choosing studies.
Dates on its pages: Public search results show a Last Updated date for each agent, but no typical entry age or guaranteed update schedule was established.
Political exposure: REPROTOX is not a government database. A VA contract signed May 27, 2022 was a federal purchase, not evidence of government editorial control; the reviewed records found no documented political interference or partisan content change from 2015 through 2026.
Money exposure: Paid access includes commercial institutional subscriptions, and its 2026 public filing summary does not name contribution sources. The audit found no pharmaceutical sponsor disclosure, product-company editorial control, or documented sponsor influence; a 2022 VA purchase order was customer revenue, not pharma funding.
Track record: The audit found no source-specific correction or retraction record and no independent, comprehensive accuracy review. A public sample provides numbered references and the search page shows update dates, but those features alone do not establish accuracy.

Where this comes from

Incentive exposure describes pressure from money or politics, not whether the source is right. Funding alone does not show influence.

← Back to Our sources